2022
DOI: 10.1002/elan.202200295
|View full text |Cite
|
Sign up to set email alerts
|

Voltammetric Determination of Favipiravir Used as an Antiviral Drug for the Treatment of Covid‐19 at Pencil Graphite Electrode

Abstract: This work describes the sensitive voltammetric determination of favipiravir (FAV) based on its reduction for the first time with a low‐cost and disposable pencil graphite electrode (PGE). In addition, the determination of FAV was also performed based on its oxidation. Differential pulse (DP) voltammograms recorded in 0.5 M H 2 SO 4 for the reduction of FAV show that peak currents increase linearly in the range of 1.0 to 600.0 μM with a limit of detection of 0.35 μM… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

1
12
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 16 publications
(17 citation statements)
references
References 47 publications
1
12
0
Order By: Relevance
“…Favipiravir (chemical name: 6-fluoro-3-hydroxypyrazine-2-carboxamide, molecular formula: C 5 H 4 FN 3 O 2 , molecular weight: 157.104), a potent RdRp inhibitor and purine nucleic acid analog, was first developed by Toyama Chemical Company in 2014. It has antiviral properties against influenza viruses due to modified pyrazine analogs; , therefore, it has been used as an antiviral medication against Lassa virus, Ebola virus, and SARS-CoV-2. , The crystallization process investigation of favipiravir is crucial due to its exceptional potential for mass production. The nucleation study could help us to understand and control the key parameters, enabling the optimization of the whole crystallization process.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Favipiravir (chemical name: 6-fluoro-3-hydroxypyrazine-2-carboxamide, molecular formula: C 5 H 4 FN 3 O 2 , molecular weight: 157.104), a potent RdRp inhibitor and purine nucleic acid analog, was first developed by Toyama Chemical Company in 2014. It has antiviral properties against influenza viruses due to modified pyrazine analogs; , therefore, it has been used as an antiviral medication against Lassa virus, Ebola virus, and SARS-CoV-2. , The crystallization process investigation of favipiravir is crucial due to its exceptional potential for mass production. The nucleation study could help us to understand and control the key parameters, enabling the optimization of the whole crystallization process.…”
Section: Introductionmentioning
confidence: 99%
“…It has antiviral properties against influenza viruses due to modified pyrazine analogs; 22,23 therefore, it has been used as an antiviral medication against Lassa virus, 24 Ebola virus, 25 and SARS-CoV-2. 26,27 The crystallization process investigation of favipiravir is crucial due to its exceptional potential for mass production. The nucleation study could help us to understand and control the key parameters, enabling the optimization of the whole crystallization process.…”
Section: Introductionmentioning
confidence: 99%
“…The coronavirus disease, known as coronavirus 2 (SARS-CoV-2), which manifests itself with acute respiratory syndrome, is a very dangerous viral disease [ 1 ]. SARS-CoV-2 (aka COVID-19), which first appeared in Wuhan, China, on December 2019, still affects the world through its various variants such as Omicron, Delta, and Ba.2–5 [ 2 ]. This viral disease manifests itself with mild symptoms and also causes serious diseases such as multi-organ failure, arrhythmias, shock, kidney and heart failure in advanced stages resulting in death [ 2 ].…”
Section: Introductionmentioning
confidence: 99%
“…SARS-CoV-2 (aka COVID-19), which first appeared in Wuhan, China, on December 2019, still affects the world through its various variants such as Omicron, Delta, and Ba.2–5 [ 2 ]. This viral disease manifests itself with mild symptoms and also causes serious diseases such as multi-organ failure, arrhythmias, shock, kidney and heart failure in advanced stages resulting in death [ 2 ]. COVID-19 caused a pandemic declaration by the World Health Organization (WHO) in March 2020 due to a major public health emergency [ 3 ].…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation